International Journal of Chronic Diseases (Jan 2016)

Screening for Nephropathy in Diabetes Mellitus: Is Micral-Test Valid among All Diabetics?

  • Koubaa Afifa,
  • Sriha Belguith Asma,
  • Harzallah Nabil,
  • Bellaleh Ahlem,
  • Sahtout Mounira,
  • Younes Kawthar,
  • Triki Sonia,
  • Hellara Ilhem,
  • Neffati Fadoua,
  • Najjar Fadhel,
  • Soltani Mohamed

DOI
https://doi.org/10.1155/2016/2910627
Journal volume & issue
Vol. 2016

Abstract

Read online

Background. Using Micral-test (MT) for screening microalbuminuria (MA) among type 2 diabetics (T2D) is helpful. We aimed at determining prevalence of MA and at describing the MT validity. Methods. We studied 182 T2D followed up in family medicine. Two 24-hour urinary quantitative assays of MA had been used as a gold standard. Results. Prevalence of MA was 23%, CI 95%: 16.9–29.1. MT validity was 77% for sensitivity, 88% for negative predictive value, and 0.2 for Kappa coefficient (p=0.001). Among subjects having a blood pressure ≥130/80 mmHg, having a CHT/HDL ratio ≥ 3, being a T2D for more than 5 years, and being women, negative predictive values were, respectively, 91%, 89%, 95%, and 91%. The area under the ROC curve was 0.81 in men (p=0.008) and 0.80 when diabetes duration exceeds 5 years (p=0.001). The MA value at 100% Sp for MT was 35 mg/L. Conclusion. The use of MT in primary healthcare for yearly screening for MA in T2D must be accentuated especially when diabetes duration exceeds 5 years or when associated with other cardiovascular risks.